Ketoanalogue for Kidney Disease Market (Application: Chronic Kidney Disease, Acute Renal Failure, and Others) - Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global ketoanalogue for kidney disease market size was exhibited at USD 234.63 million in 2022 and is projected to hit around USD 448.78 million by 2032, growing at a CAGR of 6.7% during the forecast period 2023 to 2032.

Key Pointers:

• In terms of application, the chronic kidney disease segment accounted for significant market share in 2022.
• The hospital pharmacies segment is likely to account for major share of the global ketoanalogue for kidney disease market during the forecast period.
• North America accounted for the largest share of around 43.9% of the global ketoanalogue for kidney disease market in 2022.

Ketoanalogue for Kidney Disease Market Report Scope

Alpha ketoanalogue belongs to a class of drugs called nutritional or dietary supplements. It is widely used in the treatment of kidney disease. Chronic kidney disease (CKD) is a long-term condition, where the kidneys do not function properly. It is usually caused by various conditions such as high blood pressure, diabetes, high cholesterol, kidney infections, kidney inflammation, recurring kidney stones, or an enlarged prostate; and long-term, regular use of certain medicines such as lithium; and non-steroidal anti-inflammatory drugs (NSAIDs).

Dietary factors could affect the progression of chronic kidney disease and its complications. Progression of chronic kidney disease leads to end-stage of renal disease (ESRD), which currently has no cure. Among CKD patients, overnutrition results in hyperphosphatemia, hyperkalemia, sodium/volume overload, and accumulation of toxic metabolites of protein degradation. The current strategy for controlling CKD is relatively conservative and aims to delay the time for dialysis and to relieve symptoms & signs caused by CKD-related comorbidities. Ketosteril is one of the ketoanalogue supplements that could slow down the progression of CKD. Ketoanalogues supplement intervention in pre-ESRD patients with eGFR > 18 could prevent renal function deterioration. Alfa ketoanalogue in CKD helps prevent CKD progression; however, early intervention can also effectively slow down this progression.

The global ketoanalogue for kidney disease market is driven by increase in incidence of kidney disease and rise in usage of ketoanalogue supplement in kidney disease management. Surge in awareness about the importance of nutrition management in kidney diseases is likely to augment the global market.

Increase in Incidence of Kidney Disease to Drive Global Market

The burden of various chronic kidney diseases across the globe is expected to rise significantly in the next few years. According to the National Kidney Foundation, around 12% of the global population is affected by chronic kidney disease (CKD), and millions die each year because they do not have access to affordable critical and chronic care products. According to the Centers for Disease Control and Prevention (CDC), a staggering 37 million adults are estimated to have kidney disease in the U.S. Additionally, increase in incidence of chronic diseases associated with the kidneys is another major factor driving the global ketoanalogue for kidney disease market. Diabetes, hypertension, osteoarthritis, chronic obstructive pulmonary disease (COPD), asthma, and depressive disorders are the major chronic diseases associated with the kidneys. Diabetes and hypertension are the major causes of kidney failure. According to the International Diabetes Federation, 425 million people were living with diabetes globally in 2016, and over 10% of the world’s adult population (645 million) is projected to have diabetes by 2040.

Increase in usage of ketoanalogue supplement in the treatment of kidney diseases is likely to drive the global ketoanalogue for kidney disease market size during the forecast period. Dietary protein plays a crucial role in the management of kidney diseases, and low protein diet (LPD) is typically advised to CKD patients to reduce uremic symptoms and slow the advancement of renal dysfunction. Alpha ketoanalogue is a form of essential amino acid. It provides metabolic benefit to the body. Alpha ketoanalogue in CKD is most commonly used as nutrition therapy or dietary supplements. This medicine prevents the unnecessary increase in urea levels in the blood due to the intake of non-essential amino acids in patients with kidney failure.

Surge in Preference for Alfa Ketoanalogue in CKD Management to Propel Chronic Kidney Disease Segment

In terms of application, the chronic kidney disease segment accounted for significant market share in 2022. Chronic kidney disease (CKD) occurs when the kidneys are damaged and cannot filter blood the way they should. The disease is called ‘chronic’ because the damage to the kidneys happens slowly over a long period. This damage can cause wastes to build up in the body. CKD can also cause other health issues. Alpha ketoanalogue in CKD helps slow down the progression of kidney disease, improve the quality of life, and improve calcium & phosphate metabolism. Additionally, increase in incidence of chronic kidney diseases along with associated diseases, such as diabetes and hypertension, is projected to drive the chronic kidney disease segment during the forecast period.

Favorable Reimbursement Policies Drive Preference for Hospitals to Treat CKD

Based on distribution channel, the hospital pharmacies segment is likely to account for major share of the global ketoanalogue for kidney disease market during the forecast period. Prevalence of kidney injury among hospitalized patients is a major factor that fuels the demand for kidney injury treatment at hospitals. Moreover, the number of patients being treated at hospitals is increasing due to favorable reimbursement policies. Therefore, the segment is anticipated to grow at a rapid pace during the forecast period. Rising awareness about ketoanalogue supplements and the trend of utilization of new & improved drugs by patients and physicians are expected to propel the segment.

Regional Outlook of Global Ketoanalogue for Kidney Disease Market

North America accounted for the largest share of around 43.9% of the global ketoanalogue for kidney disease market in 2022. The region is likely to be a highly lucrative market during the forecast period. North America's dominance of the global ketoanalogue for kidney disease market is ascribed to increase in incidence of kidney disease in the region. Additionally, high rate of adoption of new technologically advanced products, significant health care expenditure, early availability of advanced technologies, and increase in research activities are projected to augment the ketoanalogue for kidney disease market in North America during the forecast period. The U.S. dominated the market in the region owing to the presence of major market players and increase in the demand for ketoanalogue products in kidney diseases management.

The ketoanalogue for kidney disease market in Asia Pacific is anticipated to grow rapidly during the forecast period due to large patient base in countries, such as India and China, and rise in awareness about kidney disease treatment in the region.

Some of the prominent players in the Ketoanalogue for Kidney Disease Market include:

• Fresenius Kabi AG
• RPG Life Sciences Ltd.
• Alniche Life Sciences Pvt. Ltd.
• La Renon Healthcare Pvt. Ltd.
• Steadfast Medishield Pvt. Ltd.
• Panacea Biotec
• Element, Inc.
• Ajanta Pharma Limited
• Centaur Pharmaceuticals
• Genix Lifescience Pvt. Ltd.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Ketoanalogue for Kidney Disease market.

By Application

• Chronic Kidney Disease (CKD)
• Acute Renal Failure
• Others

By End-user

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)